Treatment with a combination of the two antibodies (casilibimab and imdebimab) is recommended for two specific groups of patients with COVID-19 by the WHO Guideline Development Group (GDG) panel of international experts and patients. BMJ today.
The first is patients with non-severe COVID-19 who are at the highest risk of hospitalization, and the second is severe or severe COVID who are seronegative, that is, they have not initiated their own antibody response to COVID-19. -19 patients.
Although the initial recommendations are based on new evidence from three trials that have not yet been peer-reviewed, Casilibimab and Indevimab are hospitalized for patients at highest risk of serious illness, such as unvaccinated and the elderly. It indicates that it probably reduces the duration of risk and symptoms. Or immunosuppressed patients.
This second recommendation Based on data from the RECOVERY trial, Casilibimab and Imdevimab probably reduce mortality (from 49 per 1,000 critically ill patients to 87 critically ill patients) and reduce the need for ventilators in seronegative patients. ..
For all other COVID-19 patients, the benefits of this antibody treatment may be meaningless.
Kasiribimab and Imdebimab Monoclonal antibody When used together, it binds to the SARS-CoV-2 peplomer and neutralizes the virus’s ability to infect cells.
Recommendations provide up-to-date and reliable guidance on the management of COVID-19, developed by the World Health Organization with the methodological support of the MAGIC Evidence Ecosystem Foundation, to help physicians make better decisions for their patients. It is a part of the life guideline to make.
Lifestyle guidelines are useful in fast-moving research areas such as COVID-19. This allows researchers to update a summary of previously scrutinized and peer-reviewed evidence as new information becomes available.
The panel acknowledged the impact of some costs and resources associated with this treatment. This can make access to low and middle income countries difficult. For example, identifying a critically ill qualified patient requires rapid serological testing, intravenous treatment using specialized equipment, and patient monitoring. Allergic reaction..
They are also aware that Casilibimab and Imdebimab may appear. antibody The effect may be reduced.
However, given the proven benefits to patients, “recommendations should provide stimuli involved in all possible mechanisms to improve global access to interventions and related tests.” It states.
Today’s guidance is in addition to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids in patients with severe or severe COVID-19. We oppose the use of ivermectin and hydroxychloroquine in patients with COVID-19, regardless of the severity of the disease.
Bram Rochwerg et al, Living WHO Guidelines on Drugs for covid-19, BMJ (2020). DOI: 10.1136 / bmj.m3379
British Medical Journal
Quote: WHO is at high risk of hospitalization obtained on September 23, 2021 from https: //medicalxpress.com/news/2021-09-antibody-treatment-covid-patients-high.html 23rd) Recommended antibody treatment for COVID patients
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
WHO recommends antibody treatment for COVID patients at high risk of hospital admission Source link WHO recommends antibody treatment for COVID patients at high risk of hospital admission
The post WHO recommends antibody treatment for COVID patients at high risk of hospital admission appeared first on California News Times.